AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1-28. (Canceled)

Claim 29. (Currently amended): A compound of the formula Id



(Id)

wherein

W is R^1-A-C(R^{13}) ~~or R^4-A-CH=C~~;

Y is a carbonyl~~, thiocarbonyl, or methylene~~ group;

Z is N(R^0);

A is ~~a bivalent radical from the group consisting of (C_1-C_6)-alkylene, (C_3-C_7)-cycloalkylene,~~ phenylene, or phenylenemethyl~~phenylene (C_1-C_6)-alkyl, (C_1-C_6)-alkylenephenyl, and phenylene (C_3-C_6)-alkenyl, or a bivalent radical of a 5- or 6-membered saturated or unsaturated ring which can contain 1 or 2 nitrogen atoms and can be mono- or disubstituted by (C_1-C_6)-alkyl or doubly bonded oxygen or sulfur~~;

B is ~~a bivalent (C_1-C_6)-alkylene~~methylene or ethylene~~-radical~~, each of which is substituted by a radical from the group consisting of (C_1-C_8)-alkyl, and (C_3-C_8)-cycloalkyl-(C_1-C_4)-alkyl~~(C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_{10})-cycloalkyl, (C_7-C_{10})-cycloalkyl-(C_1-C_6)-alkyl, optionally substituted (C_6-C_{14})-aryl, (C_6-C_{14})-aryl-(C_1-C_6)-alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl and heteroaryl-(C_1-C_6)-alkyl optionally substituted in the heteroaryl radical~~;

D is C(R^2)(R^3)~~, N(R^4), or CH=C(R^4)~~;

E is ~~tetrazolyl, (R^8O)$_2$P(O), HOS(O)$_2$, R^9NHS(O)$_2$, or~~ R^{10}CO;

R is hydrogen, methyl or ethyl~~(C_1-C_8)-alkyl, (C_4-C_8)-cycloalkyl, optionally substituted (C_6-C_{14})-aryl, or (C_6-C_{14})-aryl-(C_1-C_6)-alkyl optionally substituted in the aryl radical~~;

R^9 is ~~hydrogen, (C_1-C_8)-alkyl, (C_3-C_{12})-cycloalkyl, (C_7-C_{12})-cycloalkyl-(C_1-C_8)-alkyl, (C_6-C_{12})-~~

~~bicycloalkyl, (C_6-C_{12}) bicycloalkyl (C_1-C_8) alkyl, (C_6-C_{12}) tricycloalkyl, (C_6-C_{12}) tricycloalkyl (C_1-C_8) alkyl, optionally substituted (C_6-C_{14}) aryl, (C_6-C_{14}) aryl (C_1-C_8) alkyl, (C_6-C_{14}) aryl-(C_1-C_8) alkyl~~ optionally substituted in the aryl radical, ~~optionally substituted heteroaryl, heteroaryl (C_1-C_8) alkyl optionally substituted in the heteroaryl radical, CHO, (C_1-C_8) alkyl-CO, (C_3-C_{12}) cycloalkyl-CO, (C_3-C_{12}) cycloalkyl (C_1-C_8) alkyl-CO, (C_6-C_{12}) bicycloalkyl-CO, (C_6-C_{12}) bicycloalkyl (C_1-C_8) alkyl-CO, (C_6-C_{12}) tricycloalkyl-CO, (C_6-C_{12}) tricycloalkyl (C_1-C_8) alkyl-CO, optionally substituted (C_6-C_{14}) aryl-CO, (C_6-C_{14}) aryl-(C_1-C_8) alkyl-CO optionally substituted in the aryl radical, optionally substituted heteroaryl-CO, heteroaryl (C_1-C_8) alkyl-CO optionally substituted in the heteroaryl radical, (C_1-C_8) alkyl-S(O)$_n$, (C_3-C_{12}) cycloalkyl-S(O)$_n$, (C_3-C_{12}) cycloalkyl (C_1-C_8) alkyl-S(O)$_n$, (C_6-C_{12}) bicycloalkyl-S(O)$_n$, (C_6-C_{12}) bicycloalkyl (C_1-C_8) alkyl-S(O)$_n$, (C_6-C_{12}) tricycloalkyl-S(O)$_n$, (C_6-C_{12}) tricycloalkyl (C_1-C_8) alkyl-S(O)$_n$, optionally substituted (C_6-C_{14}) aryl-S(O)$_n$, (C_6-C_{14}) aryl (C_1-C_8) alkyl-S(O)$_n$, optionally substituted in the aryl radical, optionally substituted heteroaryl-S(O)$_n$, or heteroaryl (C_1-C_8) alkyl-S(O)$_n$, optionally substituted in the heteroaryl radical, wherein n is 1 or 2~~;

R^1 is ~~X-NH-C(=NH)-(CH$_2$)$_p$, or X^1-NH-(CH$_2$)$_p$, wherein p is 0, 1, 2, or 3~~ X-NH-C(=N-H), X-NH-C(=NX)-NH or X-NH-CH$_2$;

X is hydrogen, ~~(C_1-C_8) alkyl, (C_1-C_8) alkylcarbonyl, (C_1-C_8) alkoxycarbonyl, (C_1-C_{48}) alkylcarbonyloxy, (C_1-C_8) alkoxycarbonyl, optionally substituted (C_6-C_{14}) arylcarbonyl, optionally substituted (C_6-C_{14}) aryloxycarbonyl, (C_6-C_{14}) aryl (C_1-C_8) alkoxycarbonyl which can also be substituted in the aryl radical, (R^5O)$_2$P(O), cyano, hydroxyl, (C_1-C_8) alkoxy, (C_6-C_{14}) aryl (C_1-C_8) alkoxy which can also be substituted in the aryl radical, or amine~~;

~~X^1 has one of the meanings of X or is R'-NH-C(=N-R")$_n$, wherein R' and R", independently of one another, have the meanings of X~~;

R^2 is hydrogen, or (C_1-C_8)-alkyl, ~~optionally substituted (C_6-C_{14}) aryl, (C_6-C_{14}) aryl (C_1-C_8) alkyl optionally substituted in the aryl radical or (C_3-C_8) cycloalkyl~~;

R^3 is ~~hydrogen, (C_1-C_8) alkyl,~~ optionally substituted (C_6-C_{14})-aryl, ~~(C_6-C_{14}) aryl (C_1-C_8) alkyl optionally substituted in the aryl radical, (C_3-C_8) cycloalkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, (C_2-C_8) alkenylcarbonyl, (C_2-C_8) alkynylcarbonyl, pyridyl,~~ R^{11}NH, ~~R^4CO, COOR^4, CON(CH$_3$)R^{14},~~ or CONHR^{14}, ~~CSNHR^{14}, COOR^{15}, CON(CH$_3$)R^{15}, or CONHR^{15}~~;

~~R^4 is hydrogen or (C_1-C_{28}) alkyl which can optionally be mono- or polysubstituted by identical or different radicals R^6~~;

~~R^4 is hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or di-((C_1-C_{18})-alkyl)aminocarbonyl, amino-(C_2-C_{18})-alkylaminocarbonyl, amino-(C_1-C_2)-alkylphenyl-(C_1-C_3)-alkylaminocarbonyl, (C_1-C_{68})-alkylcarbonylamino-(C_1-C_3)-alkylphenyl-(C_1-C_3)-alkylaminocarbonyl, (C_1-C_{18}) alkylcarbonylamino-(C_2-C_{18})-alkylaminocarbonyl, (C_6-C_{14}) aryl-(C_1-C_8)-alkoxycarbonyl which can also be substituted in the aryl radical, amino,~~

~~mercapto, (C_1-C_{18})-alkoxy, (C_4-C_{14})-alkoxycarbonyl, optionally substituted (C_3-C_8)-cycloalkyl, halogen, nitro, trifluoromethyl, or the radical R^5;~~

R^5 is optionally substituted (C_6-C_{14})-aryl, ~~(C_6-C_{14})-aryl-(C_1-C_8)-alkyl optionally substituted in the aryl radical, a mono- or bicyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated, or completely hydrogenated, and which can contain one, two, or three identical or different heteroatoms from the group consisting of nitrogen, oxygen, and sulfur, a radical R^6 or a radical R^6CO,~~ wherein the aryl radical ~~and, independently thereof, the heterocyclic radical~~ can be mono- or polysubstituted by identical or different radicals from the group consisting of (C_1-C_{18})-alkyl, ~~(C_1-C_{18})-alkoxy,~~ and halogen~~, nitro, amino, and trifluoromethyl~~;

~~R^6 is R^7R^8N, R^7O or R^7S, or an amino acid side chain, a natural or unnatural amino acid, imino acid, optionally N-(C_1-C_8)-alkylated or N-$((C_6-C_{14})$-aryl-(C_1-C_8)-alkylated) azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or wherein the peptide bond can be reduced to $-NH-CH_2-$, and their esters and amides, wherein hydrogen or hydroxymethyl can optionally stand in place of free functional groups and/or where free functional groups can be protected by protective groups customary in peptide chemistry;~~

~~R^7 is hydrogen, (C_1-C_{18})-alkyl, (C_6-C_{14})-aryl-(C_1-C_8)-alkyl, (C_1-C_{18})-alkylcarbonyl, (C_1-C_{18})-alkoxycarbonyl, (C_6-C_{14})-arylcarbonyl, (C_6-C_{14})-aryl-(C_1-C_8)-alkylcarbonyl or (C_6-C_{14})-aryl-(C_1-C_{18})-alkyloxycarbonyl, wherein the alkyl groups can optionally be substituted by an amino group and/or where the aryl radicals can be mono- or polysubstituted by identical or different radicals from the group consisting of (C_1-C_8)-alkyl, (C_1-C_8)-alkoxy, halogen, nitro, amino and trifluoromethyl, or is a natural or unnatural amino acid, imino acid, optionally N-(C_1-C_8)-alkylated or N-$((C_6-C_{14})$-aryl-(C_1-C_8)-alkylated) azaamino acid or a dipeptide radical which can also be substituted in the aryl radical and/or wherein the peptide bond can be reduced to $-NH-CH_2-$;~~

~~R^8 is hydrogen, (C_1-C_{18})-alkyl, optionally substituted (C_6-C_{14})-aryl or (C_6-C_{14})-aryl-(C_1-C_8)-alkyl which can also be substituted in the aryl radical;~~

~~R^9 is hydrogen, aminocarbonyl, (C_1-C_{18})-alkylaminocarbonyl, (C_3-C_8)-cycloalkylaminocarbonyl, optionally substituted (C_6-C_{14})-arylaminocarbonyl, (C_1-C_{18})-alkyl, optionally substituted (C_6-C_{14})-aryl or (C_3-C_8)-cycloalkyl;~~

R^{10} is hydroxyl, ~~or (C_1-C_8)-alkoxy (C_1-C_{18})-alkoxy, (C_6-C_{14})-aryl-(C_1-C_8)-alkoxy which can also be substituted in the aryl radical, optionally substituted (C_6-C_{14})-aryloxy, amino or mono- or di-$((C_1-C_{18})$-alkyl)amino;~~

R^{11} is ~~hydrogen, (C_1-C_{18})-alkyl, $R^{12}CO$, optionally substituted (C_6-C_{14})-aryl-$S(O)_2$, (C_1-C_{18})-alkyl-$S(O)_2$, (C_6-C_{14})-aryl-(C_1-C_8)-alkyl optionally substituted in the aryl radical or $R^5NHS(O)_2$;~~

R^{12} is ~~hydrogen, (C_1-C_{18})-alkyl, (C_2-C_8)-alkenyl, (C_2-C_8)-alkynyl, optionally substituted (C_6-C_{14})-aryl, (C_1-C_{18})-alkoxy, (C_6-C_{14})-aryl-(C_1-C_8)-alkoxy which can also be substituted in~~

~~the aryl radical, optionally substituted (C_6-C_{14}) aryloxy, amino or mono- or di ((C_1-C_{18})-alkyl)amino~~;

R^{13} is hydrogen, or (C_1-C_6)-alkyl, ~~(C_6-C_{14}) aryl (C_1-C_8) alkyl optionally substituted in the aryl radical or (C_3-C_8) cycloalkyl~~;

R^{14} is ~~hydrogen or (C_1-C_{28}) alkyl~~ (C_1-C_{10})-alkyl which is substitutedby a radical selected from the group consisting of hydroxycarbonyl and (C_1-C_8)-alkoxycarbonyl and can optionally be substituted by a radical ~~mono- or polysubstituted by identical or different radicals from the group consisting of hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or di-((C_1-C_{18})-alkyl)aminocarbonyl, amino (C_3-C_{18}) alkylaminocarbonyl, amino (C_1-C_3) alkylphenyl (C_1-C_3) alkylaminocarbonyl, (C_1-C_{18}) alkylcarbonylamino (C_1-C_3) alkylphenyl (C_1-C_3) alkylaminocarbonyl, (C_1-C_{18}) alkylcarbonylamino (C_3-C_{18}) alkylaminocarbonyl, (C_6-C_{14}) aryl (C_1-C_8) alkoxycarbonyl which can also be substituted in the aryl radical, amino, mercapto, (C_1-C_{18}) alkoxy, (C_1-C_{18}) alkoxycarbonyl, optionally substituted (C_3-C_8) cycloalkyl, HOS(O)$_2$, (C_1-C_3) alkyl, R^8NHS(O)$_2$ (C_1-C_3) alkyl, (R^8O)$_2$P(O) (C_1-C_3) alkyl, tetrazolyl (C_1-C_3) alkyl, halogen, nitro, trifluoromethyl and R^5~~;

~~R^{15} is R^{16} (C_1-C_6) alkyl or R^{16};~~

~~R^{16} is a 6- to 24-membered bicyclic or tricyclic radical which is saturated or partially unsaturated and which can also contain one to four identical or different heteroatoms from the group consisting of nitrogen, oxygen, and sulfur and which can also be substituted by one or more identical or different substituents from the group consisting of (C_1-C_4)-alkyl and oxo;~~

c, and d, are 1; ~~and~~

f and g are 0, ~~independently of one another, are 0 or 1, but cannot all simultaneously be 0~~;

e, ~~f,~~ and h, independently of one another, are 0, or 1, ~~2, 3, 4, 5, or 6~~;

~~in all~~or its stereoisomeric forms ~~and~~or a mixtures thereof in any ratio, ~~and~~/or ~~its~~a physiologically tolerable salts thereof.

Claim 30. (currently amended) The compound of claim 29, wherein

~~W is R^1-A-C(R^{13})~~;

~~Y is a carbonyl group;~~

~~A is a bivalent radical from the group consisting of (C_3-C_7)-cycloalkylene, phenylene, phenylene (C_1-C_6) alkyl, (C_1-C_6)-alkylenephenyl [[or]] and a bivalent radical of a 5- or 6-membered saturated or unsaturated ring which can contain 1 or 2 nitrogen atoms and can be mono- or disubstituted by (C_1-C_6)-alkyl or doubly bonded oxygen or sulfur;~~

~~B is a bivalent methylene radical or ethylene radical which is substituted by a radical from the group consisting of (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, (C_3-C_{10})-cycloalkyl, (C_3-C_{10})-cycloalkyl (C_1-C_6)-alkyl, optionally substituted (C_6-C_{14}) aryl, (C_6-C_{14})-aryl (C_1-C_6)-alkyl optionally substituted in the aryl radical, optionally substituted heteroaryl, and~~

heteroaryl-(C_1-C_8)-alkyl optionally substituted in the heteroaryl radical;

D is $C(R^3)(R^3)$;

E is tetrazolyl or $R^{10}CO$;

R is hydrogen or (C_1-C_8)-alkyl;

X is hydrogen, (C_1-C_6)-alkyl, (C_1-C_6)-alkylcarbonyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_{18})-alkylcarbonyloxy-(C_1-C_6)-alkoxycarbonyl, optionally substituted (C_6-C_{14})-arylcarbonyl, optionally substituted (C_6-C_{14})-aryloxycarbonyl, (C_6-C_{14})-aryl-(C_1-C_6)-alkoxycarbonyl which can also be substituted in the aryl radical, cyano, hydroxyl, (C_1-C_6)-alkoxy, (C_6-C_{14})-aryl-(C_1-C_6)-alkoxy which can also be substituted in the aryl radical, or amino;

R^3 is hydrogen or (C_1-C_8)-alkyl;

R^4 is hydrogen, (C_1-C_8)-alkyl, optionally substituted (C_6-C_{14})-aryl, (C_6-C_{14})-aryl-(C_1-C_8)-alkyl optionally substituted in the aryl radical, (C_3-C_8)-cycloalkyl, (C_2-C_8)-alkenyl, (C_3-C_8)-alkynyl, (C_2-C_8)-alkenylcarbonyl, (C_2-C_8)-alkynylcarbonyl, pyridyl, $R^{14}NH$, $CON(CH_2)R^{14}$, $CONHR^{14}$, $CON(CH_2)R^{15}$, or $CONHR^{15}$;

R^5 is optionally substituted (C_6-C_{14})-aryl, (C_6-C_{14})-aryl-(C_1-C_8)-alkyl optionally substituted in the aryl radical, a mono- or bicyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated, or completely hydrogenated and which can contain one, two, or three identical or different heteroatoms from the group consisting of nitrogen, oxygen and sulfur, or a radical R^9CO, wherein the aryl radical and, independently thereof, the heterocyclic radical, can be mono- or polysubstituted by identical or different radicals from the group consisting of (C_1-C_8)-alkyl, (C_1-C_8)-alkoxy, halogen, nitro, amino, or trifluoromethyl;

R^9 is a natural or unnatural amino acid, imino acid, optionally N-(C_1-C_8)-alkylated or N-((C_6-C_{14})-aryl-(C_1-C_8)-alkylated) azaamino acid or a dipeptide radical which can also be substituted in the aryl radical, and their esters and amides, wherein free functional groups can be protected by protective groups customary in peptide chemistry;

R^{11} is $R^{10}CO$, optionally substituted (C_6-C_{14})-aryl-$S(O)_2$- or (C_1-C_{18})-alkyl-$S(O)_2$-;

R^{12} is hydrogen, (C_1-C_{18})-alkyl, (C_2-C_8)-alkenyl, (C_2-C_8)-alkynyl, optionally substituted (C_6-C_{14})-aryl, (C_1-C_{18})-alkoxy, (C_6-C_{14})-aryl-(C_1-C_8)-alkoxy which can also be substituted in the aryl radical or optionally substituted (C_6-C_{14})-aryloxy;

R^{13} is hydrogen or (C_1-C_4)-alkyl;

R^{14} is (C_1-C_{40})-alkyl which can optionally be mono- or polysubstituted by identical or different radicals from the group consisting of hydroxyl, hydroxycarbonyl, aminocarbonyl, mono- or di-((C_1-C_{40})-alkyl)amino-carbonyl, (C_6-C_{14})-aryl-(C_1-C_8)-alkoxycarbonyl which can also be substituted in the aryl radical, (C_1-C_8)-alkoxy, (C_1-C_8)-alkoxycarbonyl, optionally substituted (C_3-C_8)-cycloalkyl, tetrazolyl-(C_1-C_3)-alkyl, trifluoromethyl and R^5;

e and d are 1, and f is 0;

e and h, independently of one another, are 0 or 1, and g is 0

or its stereoisomeric form or a mixture thereof in any ratio, or a physiologically tolerable salt thereof.

Claim 31. (Currently amended) The compound of claim 29, wherein

B is methylene or ethylene, each of which is substituted by a (C_1-C_8)-alkyl radical, or its stereoisomeric form or a mixture thereof in any ratio, or a physiologically tolerable salt thereof.

Claim 32. (Currently amended) A pharmaceutical composition comprising ~~one or more~~the compounds of claim 29, or its stereoisomeric form or a mixture thereof in any ratio, or a physiologically tolerable salt thereof, and a pharmaceutically acceptable carrier.

Claims 33-39. (Canceled)

Claim 40. (Currently amended) A method of treating a disease or disorder involving inflammation, comprising administering to a subject in need thereof an effective amount of ~~the pharmaceutical composition of claim 32~~compound of claim 29, or its stereoisomeric form or a mixture thereof in any ratio, or a physiologically tolerable salt thereof.

Claim 41. (Canceled)

Claim 42. (Currently amended) A method of treating a disease or disorder selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, an inflammatory disorders of the central nervous system, asthma, allergy~~ies~~, a cardiovascular disorders, arteriosclerosis, multiple sclerosis, restenoses, diabetes, damage to organ transplants, tumor growth, tumor metastasis, melanoma, lymphoma, and malaria, comprising administering to a subject in need thereof an effective amount of ~~the pharmaceutical composition of claim 32~~compound of claim 29, or its stereoisomeric form or a mixture thereof in any ratio, or a physiologically tolerable salt thereof..

Claim 43. (Currently amended) A method of treating a disease or disorder, wherein said disease or disorder exhibits an abnormally large amount of leucocyte adhesion and/or migration, comprising administering to a subject in need thereof an effective amount of ~~the pharmaceutical composition of claim 32~~compound of claim 29, or its stereoisomeric form or a mixture thereof in any ratio, or a physiologically tolerable salt thereof..